Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

计划入组 80 人 · 首次发布于 2026 年 7 月 2 日

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

计划入组 24 人 · 首次发布于 2025 年 6 月 26 日

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

计划入组 24 人 · 首次发布于 2025 年 6 月 26 日

ENTR-601-45

ENTR-601-44

ENTR-601-50

Ente Ospedaliero Ospedali Galliera

Italy

Reliance Life Sciences Pvt Ltd.

India

浙江恒研医药科技有限公司

Entrada Therapeutics Advances RNA-Based Pipeline with First Ocular Candidate for Usher Syndrome

Entrada Therapeutics Advances DMD Treatment: UK MHRA Approves Phase I/II Trial for Novel Exon-Skipping Therapy

Phase 1 Trial Shows Promise for PSCA-Targeted BPX-601 CAR T-Cell Therapy in Pancreatic and Prostate Cancers